miltefosine has been researched along with Chronic Disease in 3 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "After 4 weeks of treatment, Urticaria Activity Score (UAS7) levels were substantially more reduced in miltefosine-treated patients (-6." | 9.17 | Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. ( Bieber, T; Biedermann, T; Brasch, J; Dominicus, R; Hunzelmann, N; Jakob, T; Magerl, M; Mahler, V; Maurer, M; Popp, G; Rother, M; Schäkel, K; Schlingensiepen, R; Schmitt, J; Siebenhaar, F; Simon, JC; Staubach, P; Wedi, B; Weidner, C, 2013) |
| "After 4 weeks of treatment, Urticaria Activity Score (UAS7) levels were substantially more reduced in miltefosine-treated patients (-6." | 5.17 | Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. ( Bieber, T; Biedermann, T; Brasch, J; Dominicus, R; Hunzelmann, N; Jakob, T; Magerl, M; Mahler, V; Maurer, M; Popp, G; Rother, M; Schäkel, K; Schlingensiepen, R; Schmitt, J; Siebenhaar, F; Simon, JC; Staubach, P; Wedi, B; Weidner, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Mano, C | 1 |
| Kongkaew, A | 1 |
| Tippawangkosol, P | 1 |
| Junkum, A | 1 |
| Siriyasatien, P | 1 |
| Jariyapan, N | 1 |
| Magerl, M | 1 |
| Rother, M | 1 |
| Bieber, T | 1 |
| Biedermann, T | 1 |
| Brasch, J | 1 |
| Dominicus, R | 1 |
| Hunzelmann, N | 1 |
| Jakob, T | 1 |
| Mahler, V | 1 |
| Popp, G | 1 |
| Schäkel, K | 1 |
| Schlingensiepen, R | 1 |
| Schmitt, J | 1 |
| Siebenhaar, F | 1 |
| Simon, JC | 1 |
| Staubach, P | 1 |
| Wedi, B | 1 |
| Weidner, C | 1 |
| Maurer, M | 1 |
| Vasseneix, C | 1 |
| Gargala, G | 1 |
| François, A | 1 |
| Hellot, MF | 1 |
| Duclos, C | 1 |
| Muraine, M | 1 |
| Benichou, J | 1 |
| Ballet, JJ | 1 |
| Brasseur, G | 1 |
| Favennec, L | 1 |
1 trial available for miltefosine and Chronic Disease
| Article | Year |
|---|---|
Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria.
Topics: Chronic Disease; Double-Blind Method; Histamine Antagonists; Humans; Phosphorylcholine; Placebos; Ur | 2013 |
2 other studies available for miltefosine and Chronic Disease
| Article | Year |
|---|---|
In vitro susceptibility to miltefosine of amphotericin B-resistant Leishmania (Mundinia) martiniquensis.
Topics: Amphotericin B; Antiprotozoal Agents; Chronic Disease; Humans; Leishmania; Leishmaniasis; Leishmania | 2023 |
A keratitis rat model for evaluation of anti-Acanthamoeba polyphaga agents.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Administration, Topical; Animals; Antiprotozoal Agents; Benzam | 2006 |